US 12,281,085 B2
Bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
Matti Davis, Modiin (IL); Bruce S. Fischer, East Brunswick, NJ (US); and Gaurav Bajaj, Plainsboro, NJ (US)
Assigned to Immunome, Inc., Bothell, WA (US); and Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed by Ayala Pharmaceuticals Inc., Wilmington, DE (US); and Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed on Oct. 22, 2020, as Appl. No. 17/077,857.
Application 17/077,857 is a continuation in part of application No. PCT/US2019/030771, filed on May 5, 2019.
Claims priority of provisional application 62/667,540, filed on May 6, 2018.
Prior Publication US 2021/0040050 A1, Feb. 11, 2021
Int. Cl. C07D 243/14 (2006.01); A61K 9/00 (2006.01); A61K 31/203 (2006.01); A61K 31/44 (2006.01); A61K 31/5513 (2006.01); A61K 31/635 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01)
CPC C07D 243/14 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 31/203 (2013.01); A61K 31/44 (2013.01); A61K 31/5513 (2013.01); A61K 31/635 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01)] 10 Claims
 
1. A composition comprising a compound represented by the structure of Compound (1):

OG Complex Work Unit Chemistry
and/or at least one salt thereof
in combination with a composition comprising a CDK 4 and 6 inhibitor, sorafenib, regorafenib, venetoclax, vorinostat, or a combination thereof.